Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: A pilot study

36Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

Abstract

Objective: To evaluate 3 Tesla (T) whole-body diffusion-weighted magnetic resonance imaging (WB DWI) for early treatment assessment in aggressive non-Hodgkin lymphoma (NHL). Methods: Fourteen patients with NHL treated with standard chemotherapy underwent 3-T WB DWI before and 2 and 4 weeks during treatment, using b-values of 0-1000 s/mm2 from which the apparent diffusion coefficient (ADC) was calculated. Patient follow-up (average 20.3 months, range 15-23 months) was the reference standard. Volume and ADC changes between baseline and 2 weeks (Vratio2w, ADCratio2w) and 4 weeks (Vratio4w, ADCratio4w) of responding and non-responding lesions (lymph node and organ lesions) were compared using Mann-Whitney U tests. The per patient values of VratioN and ADCratioN to predict progression-free survival were determined with a log-rank test. Results: Eight patients showed complete remission and 6 showed tumour progression. The ADCratio2w and ADCratio4wdiffered significantly in lesions showing tumour progression versus complete remission (ADCratio 2w-4±21% versus 119±68%; ADCratio4w= 18±61% versus 155±78%; both P50.0001); the Vratio2w and Vratio4w did not (P40.05). Per body region, the ADCratio 2w showed a negative predictive value of 100% and positive predictive value of 86%. Per patient, the ADCratio2w and ADCratio4w correlated significantly with progression-free survival (P50.05). Conclusion: 3-T WB DWI with ADC quantification may enable early treatment assessment of aggressive NHL. © 2013 International Cancer Imaging Society.

Cite

CITATION STYLE

APA

De Paepe, K., Bevernage, C., De Keyzer, F., Wolter, P., Gheysens, O., Janssens, A., … Vandecaveye, V. (2013). Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: A pilot study. Cancer Imaging, 13(1), 53–62. https://doi.org/10.1102/1470-7330.2013.0006

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free